Article
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.
Proceedings of the National Academy of Sciences of the United States of America - 25 Jun 2002
Ozcelik Cemil, Erdmann Bettina, Pilz Bernhard, Wettschureck Nina, Britsch Stefan, Hübner Norbert, Chien Kenneth R, Birchmeier Carmen, Garratt Alistair N
Abstract excerpt
The ErbB2 (Her2) proto-oncogene encodes a receptor tyrosine kinase, which is frequently amplified and overexpressed in human tumors. ErbB2 provides the target for a novel and effective antibody-based therapy (Trastuzumab/Herceptin) used for the treatment of mammary carcinomas. However, cardiomyopathies develop in a proportion of patients treated with Trastuzumab, and the incidence of such complications is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.